Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,619 across all filing types
Latest filing 2020-04-27 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
募集资金管理制度（2020年4月）
Governance Information Classification · 95% confidence The document is titled "深圳市海王生物工程股份有限公司募集资金管理制度 （2020年4月修订）" which translates to "Shenzhen Haiwang Bioengineering Co., Ltd. Fundraising Capital Management System (Revised April 2020)". It details the management and use of funds raised by the company through securities issuance, including regulatory compliance, storage, usage, supervision, and reporting requirements. The content is a policy or internal management system document related to the handling of raised capital, not a financial report, announcement, or regulatory filing. It does not contain financial statements, earnings data, voting results, or legal proceedings. It is a governance-related document outlining internal rules and procedures for capital management. Therefore, the most appropriate classification is Governance Information (CGR). The document length (7090 characters) and detailed procedural content support this classification with high confidence.
2020-04-27 Chinese
2019年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' which translates to 'Audit Report'. It includes detailed auditor opinions, audit basis, key audit matters such as goodwill impairment testing, revenue recognition, and bad debt provision for accounts receivable. It also contains detailed financial statements including consolidated and company balance sheets, income statements, cash flow statements, and notes to the financial statements. The presence of an auditor's signature and date further confirms this is a formal audit report. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, this document fits the category of an Audit Report / Information (AR).
2020-04-27 Chinese
独立董事关于第八届董事局第七次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors regarding their prior approval of agenda items for an upcoming board meeting, specifically about the reappointment of the 2020 external audit firm and the expected related party transactions for 2020. It references regulatory requirements for independent directors and the audit firm engagement but does not contain any financial statements or detailed audit results. The document is short (736 characters) and serves as a formal opinion or announcement related to board/management matters rather than a full audit report or annual report. Therefore, it fits best under Board/Management Information (MANG).
2020-04-27 Chinese
关于续聘2020年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the external audit firm for the fiscal year 2020. It details the audit firm's qualifications, experience, fees, and the internal approval process by the board and independent directors. It does not contain the audit report itself or detailed financial statements but rather informs shareholders and the public about the intention to continue with the same audit firm for the upcoming audit. The document length is 3751 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement (AR) because it focuses on audit-related information and the appointment of the audit firm, not the full audit report or annual report itself. FY 2020
2020-04-27 Chinese
第八届监事会第三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Shenzhen Haier Bioengineering Co., Ltd. It details the approval of various reports and proposals related to the 2019 fiscal year and the first quarter of 2020, including the 2019 Supervisory Board Work Report, 2019 Financial Final Report, 2019 Profit Distribution Plan, 2019 Annual Report, 2020 Q1 Report, asset impairment provisions, internal control self-evaluation report, remuneration proposals, audit firm renewal, and stock incentive adjustments. The document repeatedly states that the detailed reports are published elsewhere (e.g., on the official information disclosure platform 巨潮资讯网 and newspapers) and that these resolutions will be submitted to the shareholders' meeting for approval. The document itself does not contain the full financial statements or substantive financial data but rather the resolutions and approvals of these reports. The document length is under 5,000 characters, and it serves as an official announcement of the Supervisory Board's meeting resolutions rather than the reports themselves. Therefore, it fits best into the category of Regulatory Filings (RNS) as a formal announcement of supervisory board resolutions and approvals related to various reports and proposals.
2020-04-27 Chinese
关于引入投资者对子公司增资并放弃优先认缴出资权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Haiwang Bioengineering Co., Ltd. regarding the introduction of investors to increase capital in its subsidiaries and the waiver of preemptive subscription rights. It details the investment amounts, shareholding changes, and related agreements. The document includes financial data of the subsidiaries but does not present a full financial report or comprehensive financial statements. It is a corporate announcement about financing activities related to capital increase and shareholding structure changes. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is not a regulatory filing or a report publication announcement since it contains substantive details about the capital increase transaction. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-04-27 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.